ABSTRACT
Mycobacterium tuberculosis, which causes tuberculosis (TB), is estimated to infect one-third of the world's population. The overall burden and the emergence of drug-resistant strains of Mycobacterium tuberculosis underscore the need for new therapeutic options against this important human pathogen. Our recent work demonstrated the success of natural product discovery in identifying novel compounds with efficacy against Mycobacterium tuberculosis Here, we improve on these methods by combining improved isolation and Mycobacterium tuberculosis selective screening to identify three new anti-TB compounds: streptomycobactin, kitamycobactin, and amycobactin. We were unable to obtain mutants resistant to streptomycobactin, and its target remains to be elucidated. We identify the target of kitamycobactin to be the mycobacterial ClpP1P2C1 protease and confirm that kitamycobactin is an analog of the previously identified compound lassomycin. Further, we identify the target of amycobactin to be the essential protein secretion pore SecY. We show further that amycobactin inhibits protein secretion via the SecY translocon. Importantly, this inhibition is bactericidal to nonreplicating Mycobacterium tuberculosis This is the first compound, to our knowledge, that targets the Sec protein secretion machinery in Mycobacterium tuberculosis This work underscores the ability of natural product discovery to deliver not only new compounds with activity against Mycobacterium tuberculosis but also compounds with novel targets.IMPORTANCE Decreasing discovery rates and increasing resistance have underscored the need for novel therapeutic options to treat Mycobacterium tuberculosis infection. Here, we screen extracts from previously uncultured soil microbes for specific activity against Mycobacterium tuberculosis, identifying three novel compounds. We further define the mechanism of action of one compound, amycobactin, and demonstrate that it inhibits protein secretion through the Sec translocation machinery.
Subject(s)
Antitubercular Agents/pharmacology , Drug Discovery , Mycobacterium tuberculosis/drug effects , Antitubercular Agents/isolation & purification , Humans , Mycobacterium tuberculosis/enzymology , Mycobacterium tuberculosis/genetics , Protease Inhibitors/pharmacology , Tuberculosis/drug therapy , Tuberculosis/microbiologyABSTRACT
Tuberculous sputum contains multipleMycobacterium tuberculosispopulations with different requirements for isolationin vitro These include cells that form colonies on solid media (plateableM. tuberculosis), cells requiring standard liquid medium for growth (nonplateableM. tuberculosis), and cells requiring supplementation of liquid medium with culture supernatant (SN) for growth (SN-dependentM. tuberculosis). Here, we describe protocols for the cryopreservation and direct assessment of antimicrobial tolerance of theseM. tuberculosispopulations within sputum. Our results show that first-line drugs achieved only modest bactericidal effects on all three populations over 7 days (1 to 2.5 log10reductions), and SN-dependentM. tuberculosiswas more tolerant to streptomycin and isoniazid than the plateable and nonplateableM. tuberculosisstrains. Susceptibility of plateableM. tuberculosisto bactericidal drugs was significantly increased after passagein vitro; thus, tolerance observed in the sputum samples from the population groups was likely associated with mycobacterial adaptation to the host environment at some time prior to expectoration. Our findings support the use of a simpleex vivosystem for testing drug efficacies against mycobacteria that have phenotypically adapted during tuberculosis infection.
Subject(s)
Adaptation, Physiological , Antitubercular Agents/pharmacology , Biological Assay , Isoniazid/pharmacology , Mycobacterium tuberculosis/drug effects , Streptomycin/pharmacology , Cryopreservation , Drug Resistance, Bacterial/drug effects , Humans , Microbial Sensitivity Tests , Multilocus Sequence Typing , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/isolation & purification , Mycobacterium tuberculosis/physiology , Phenotype , Sputum/microbiology , Tuberculosis, Pulmonary/microbiologyABSTRACT
We have recently shown that RaaS (regulator of antimicrobial-assisted survival), encoded by Rv1219c in Mycobacterium tuberculosis and by bcg_1279c in Mycobacterium bovis bacillus Calmette-Guérin, plays an important role in mycobacterial survival in prolonged stationary phase and during murine infection. Here, we demonstrate that long chain acyl-CoA derivatives (oleoyl-CoA and, to lesser extent, palmitoyl-CoA) modulate RaaS binding to DNA and expression of the downstream genes that encode ATP-dependent efflux pumps. Moreover, exogenously added oleic acid influences RaaS-mediated mycobacterial improvement of survival and expression of the RaaS regulon. Our data suggest that long chain acyl-CoA derivatives serve as biological indicators of the bacterial metabolic state. Dysregulation of efflux pumps can be used to eliminate non-growing mycobacteria.
Subject(s)
Acyl Coenzyme A/metabolism , Bacterial Proteins/metabolism , DNA, Bacterial/metabolism , Mycobacterium/metabolism , Acyl Coenzyme A/chemistry , Amino Acid Sequence , Bacterial Proteins/genetics , Binding Sites/genetics , DNA, Bacterial/genetics , Fluorescence Polarization , Gene Expression Regulation, Bacterial/drug effects , Microbial Viability/drug effects , Microbial Viability/genetics , Molecular Sequence Data , Molecular Structure , Mutation , Mycobacterium/genetics , Mycobacterium bovis/genetics , Mycobacterium bovis/metabolism , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/metabolism , Oleic Acid/pharmacology , Palmitoyl Coenzyme A/chemistry , Palmitoyl Coenzyme A/metabolism , Protein Binding , Reverse Transcriptase Polymerase Chain Reaction , Sequence Homology, Amino Acid , Transcriptome/drug effects , Transcriptome/geneticsABSTRACT
Antimicrobials targeting cell wall biosynthesis are generally considered inactive against nonreplicating bacteria. Paradoxically, we found that under nonpermissive growth conditions, exposure of Mycobacterium bovis BCG bacilli to such antimicrobials enhanced their survival. We identified a transcriptional regulator, RaaS (for regulator of antimicrobial-assisted survival), encoded by bcg1279 (rv1219c) as being responsible for the observed phenomenon. Induction of this transcriptional regulator resulted in reduced expression of specific ATP-dependent efflux pumps and promoted long-term survival of mycobacteria, while its deletion accelerated bacterial death under nonpermissive growth conditions in vitro and during macrophage or mouse infection. These findings have implications for the design of antimicrobial drug combination therapies for persistent infectious diseases, such as tuberculosis.